Osaka spinout Cuorips has added $14.7m to its coffers from investors including CellSource and Fujifilm, just three months after collecting $19.3m.
Japan-based cell therapy developer Cuorips has secured ¥1.6bn ($14.7m) from a consortium featuring regenerative medicine manufacturer CellSource and optics and medical engineering conglomerate Fujifilm.
The round included Handai Venture NVCC I and Kyodai Venture NVCC II, which are managed by venture capital firm Nippon Venture Capital on behalf of Osaka and Kyoto universities respectively.
VC firm Jafco’s SV6 and SV6-S funds filled out the investor list together with JIC Venture Growth Fund I, operated by the government-owned JIC Growth Investments.
…
